T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

Troels Holz Borch; Rikke Andersen; Per Kongsted; ?zcan Met; Mads Hald Andersen; Per thor Straten; Marco Donia; Inge Marie Svane

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

【24h】

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

机译：T细胞疗法联合维拉非尼治疗BRAF突变的转移性黑色素瘤患者

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2014年第s3期|共页
作者
Troels Holz Borch; Rikke Andersen; Per Kongsted; ?zcan Met; Mads Hald Andersen; Per thor Straten; Marco Donia; Inge Marie Svane;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A prospective observational safety study of patients with BRAF V BRAF BRAF V V 600 600 ‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study) [J] . Corrie P.G., Terheyden P., Tije A.J., British Journal of Dermatology . 2019,第5期

机译：使用vemurafenib（Zelboraf安全研究）治疗BRAF V BRAF BRAF BRAF BRAF V V 600 600的患者的前瞻性观察安全性研究（ZELBORAF安全研究）
2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial [J] . Grob Jean Jacques, Amonkar Mayur M., Karaszewska Boguslawa, The lancet oncology . 2015,第13期

机译：达拉非尼和曲美替尼联合疗法与维拉非尼单一疗法对无法切除或转移性皮肤BRAF Val600突变阳性黑色素瘤（COMBI-v）患者健康相关生活质量的比较：一项三阶段，开放标签，随机试验
3. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF BRAF ‐mutated melanoma and other advanced malignancies [J] . Bhatty Minny, Kato Shumei, Piha‐Paul Sarina A., Cancer: A Journal of the American Cancer Society . 2019,第3期

机译：第1阶段研究vemureafenib，卡铂和紫杉醇与BRAF BRAF的患者患者的组合的研究和其他晚期恶性肿瘤
4. Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy. [C] . Spagnoli GC, Zajac P, Marti WR, World Congress on Cancers of the Skin . 2002

机译：细胞毒性T细胞诱导在经历重组疫苗病毒的免疫基因治疗中的转移性黑素瘤患者。
5. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
6. T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients [O] . Troels Holz Borch, Rikke Andersen, Per Kongsted, 2014

机译：T细胞疗法联合维拉非尼治疗BRAF突变的转移性黑色素瘤患者
7. T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients [O] . Troels Borch, Rikke Andersen, Per Kongsted, 2014

机译：T细胞疗法联合维拉非尼治疗BRAF突变的转移性黑色素瘤患者

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

著录项

引文网络

相似文献

相关主题

期刊订阅